Reduction of Coronavirus Burden With Mass Azithromycin Distribution

Thuy Doan, Armin Hinterwirth, Ahmed M Arzika, Lee Worden, Cindi Chen, Lina Zhong, Catherine E Oldenburg, Jeremy D Keenan, Thomas M Lietman, Thuy Doan, Armin Hinterwirth, Ahmed M Arzika, Lee Worden, Cindi Chen, Lina Zhong, Catherine E Oldenburg, Jeremy D Keenan, Thomas M Lietman

Abstract

We evaluated the potential antiviral effects of azithromycin on the nasopharyngeal virome of Nigerien children who had received multiple rounds of mass drug administration. We found that the respiratory burden of non-severe acute respiratory syndrome coronaviruses was decreased with azithromycin distributions. Clinical Trials Registration. NCT02047981.

Keywords: Niger; azithromycin; children; coronavirus; virome.

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Relative abundance and prevalence of respiratory viruses between placebo- and azithromycin-treated children. A, Top virus genera or species at 5% false discovery rate at 24 and 36 months. For each genus or species, the dot shows the log2 fold change (FC) with confidence bound. Values in the nonshaded area represent more relative abundance in the azithromycin-treated group, whereas values in the shaded area represent more relative abundance in the placebo-treated group. Benjamini-Hochberg correction was used to determine the adjusted P values. B, Coronavirus prevalence at 24 and 36 months. Analysis of covariance P values is shown.

References

    1. Keenan JD, Arzika AM, Maliki R, et al. Longer-term assessment of azithromycin for reducing childhood mortality in Africa. N Engl J Med 2019; 380:2207–14.
    1. Keenan JD, Arzika AM, Maliki R, et al. MORDOR-Niger Study Group Cause-specific mortality of children younger than 5 years in communities receiving biannual mass azithromycin treatment in Niger: verbal autopsy results from a cluster-randomised controlled trial. Lancet Glob Health 2020; 8:e288–95.
    1. Doan T, Hinterwirth A, Worden L, et al. Gut microbiome alteration in MORDOR I: a community-randomized trial of mass azithromycin distribution. Nat Med 2019; 25:1370–6.
    1. Schögler A, Kopf BS, Edwards MR, et al. Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. Eur Respir J 2015; 45:428–39.
    1. Retallack H, Di Lullo E, Arias C, et al. Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci U S A 2016; 113:14408–13.
    1. Doan T, Wilson MR, Crawford ED, et al. Illuminating uveitis: metagenomic deep sequencing identifies common and rare pathogens. Genome Med 2016; 8:90.
    1. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014; 15:550.
    1. Harrison PF, Pattison AD, Powell DR, Beilharz TH. Topconfects: a package for confident effect sizes in differential expression analysis provides a more biologically useful ranked gene list. Genome Biol 2019; 20:67.
    1. Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol 2020; 92:418–23.
    1. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period [manuscript published online ahead of print 14 April 2020]. Science 2020. doi:10.1126/science.abb5793.
    1. Prill MM, Iwane MK, Edwards KM, et al. New Vaccine Surveillance Network Human coronavirus in young children hospitalized for acute respiratory illness and asymptomatic controls. Pediatr Infect Dis J 2012; 31:235–40.
    1. Damle B, Vourvahis M, Wang E, Leaney J, Corrigan B. Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID-19 [manuscript published online ahead of print 17 April 2020]. Clin Pharmacol Ther 2020. doi:10.1002/cpt.1857.
    1. Ohe M, Shida H, Jodo S, et al. Macrolide treatment for COVID-19: will this be the way forward? [manuscript published online ahead of print 5 April 2020]. Biosci Trends 2020. doi:10.5582/bst.2020.03058.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit